Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesFRA:8EQ +4.23%72 Debt-to-Equity is 0.11 as of Jun. 2026, which is 175% above its 10-year median of 0.04. GuruFocus rates FRA:8EQ with a GF Score™ of 72/100 and a GF Value™ of €4.61. The stock has 6 warning signs investors should review. Among 698 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 75.36% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cytek Biosciences's Debt-to-Equity or its related term are showing as below:
FRA:8EQ'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.18 Med: 0.04 Max: 0.08
Current: 0.08
During the past 7 years, the highest Debt-to-Equity Ratio of Cytek Biosciences was 0.08. The lowest was -0.18. And the median was 0.04.
FRA:8EQ's Debt-to-Equity is ranked better than 75.36% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs FRA:8EQ: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cytek Biosciences Debt-to-Equity Related Terms
Cytek Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8EQ vs KIDS, DCTH, CERS: Debt-to-Equity Comparison
For the Medical Devices subindustry, Cytek Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (FRA:8EQ) has a Debt-to-Equity of 0.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cytek Biosciences and its competitors. This is 175% above median its historical median of 0.04. According to the industry distribution chart, Cytek Biosciences ranks #172 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 24.6%.
Is Cytek Biosciences' Debt-to-Equity too high?
Cytek Biosciences' current Debt-to-Equity of 0.11 is 175% above median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Cytek Biosciences' value of 0.11 is 54.2% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #172 out of 698 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cytek Biosciences has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Debt-to-Equity compare to KIDS and DCTH?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #172 out of 698 companies for Debt-to-Equity. This places Cytek Biosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.24. Cytek Biosciences' value of 0.11 is 54.2% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.24, Cytek Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Debt-to-Equity of 0.11 is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Debt-to-Equity is 0.11, which is 175% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Cytek Biosciences (FRA:8EQ) has a current Debt-to-Equity of 0.11. The stock's GF Value™ is €4.61, compared to a current price of €4.46 — trading 3.3% below its estimated fair value. The current Debt-to-Equity is 0.11, which is 175% above median its 10-year median of 0.04 and 54.2% below the Medical Devices & Instruments industry median of 0.24. Cytek Biosciences' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cytek Biosciences (FRA:8EQ), the current Debt-to-Equity is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (FRA:8EQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of €4.46 is trading 3.3% below its estimated GF Value™ of €4.61.
Key valuation signals for FRA:8EQ:
Debt-to-Equity: 0.11 (175% above median its 10-year median of 0.04)
GF Value™: €4.61 vs. price of €4.46 (3.3% below fair value)
Industry Position: 54.2% below the Medical Devices & Instruments median (#172 of 698)
No single metric tells the full story. See the FRA:8EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc. is a life sciences technology company that develops cell analysis systems for research and clinical applications. Its core technology, Full Spectrum Profiling (FSP), uses the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, improving sensitivity and resolution compared with conventional flow cytometry. The company's main products include the Cytek Aurora, Northern Lights, and Aurora Evo cell analyzers, along with reagents and related software. Customers include academic research institutions, pharmaceutical and biotechnology companies, and clinical laboratories. Cytek sells its instruments and consumables worldwide, generating revenue through product sales and related services, with operations spanning North America, Europe, and Asia.
72GF Score
Get the complete analysis for FRA:8EQ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8EQ has been successfully added to your 
